FAQs Archive | Page 4 of 8 | OM1 outcomes & advanced analytics

We would like to define treatment patterns for GCA patients with tocilizumab or glucocorticoids. For glucocorticoids, we need dose and days of supply information in order to track dose changes (tapering) over time. The medication dose/days of supply information can be inconsistent from my previous experience with EMR and open claims? Can you share if OM1 has used a tapering algorithm in published studies?

July 24, 2023

Our research team has not used a tapering algorithm to look at dose over time.To calculate dose for oral medications at single points in time, the team uses quantity dispensed divided by days supply multiplied by strength. Note, the Steroid Dose calculated in the dataset is an average daily dose suitable for oral and injectable[…]

If the patient does not have a Diarrhea record, can we assume the patient did not have Diarrhea?

July 24, 2023

Symptom extraction includes both affirmation and negation of the symptom. However, the absence of a record should not be interpreted as a definitive absence of the symptom.

Can patients appear in both the UC and CD datasets?

July 24, 2023

No, indeterminate IBD patients are not included in either of the UC or CD datasets.

Why aren’t there many structured CDAI scores?

July 24, 2023

While the CDAI score is used in clinical trials, it is not commonly calculated in routine clinical practice. CDAI scores are abstracted by OM1 when they do appear in the provider notes. OM1 also calculates a CDAI score when the following requisite components appear within a 4 month window in the patient’s record: Weight (used[…]

There are not as many outcomes for patients with AD as there are with Psoriasis, for example, how else does OM1 define patients with deep clinical data?

July 24, 2023July 24, 2023

Advanced treatments, including biologics, have been a mainstay of treatment for moderate-to-severe disease in PsO longer than AD and disease outcomes like a minimum %BSA serve in PsO as a threshold for initiating those therapies. There are fewer reported outcomes for AD as a condition and as a result it was determined to include all[…]